Autonomix Selected to Present at the 2024 Octane Medical Innovation Forum
Autonomix Medical, Inc. (NASDAQ: AMIX), a company focused on advancing precision nerve-targeted treatments, has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum in Irvine, California on October 8-9, 2024. The forum brings together industry experts, entrepreneurs, investors, and thought leaders to discuss the latest insights and trends in the medical industry.
Brad Hauser, CEO of Autonomix, will present on the company's minimally invasive nerve-sensing, ablation, and verification platform technology. This first-in-class technology uses a catheter-based microchip sensing array antenna that can detect and differentiate neural signals with up to 3,000 times greater sensitivity than current technologies. The platform also includes proprietary radio frequency (RF) ablation technology for targeted nerve treatment, offering a precision-guided approach to addressing various conditions from chronic pain management to hypertension and cardiology.
Autonomix Medical, Inc. (NASDAQ: AMIX), un'azienda focalizzata sull'avanzamento dei trattamenti nervosi di precisione, è stata selezionata per una presentazione in primo piano al 2024 Octane Medical Innovation Forum che si terrà a Irvine, California, il 8-9 ottobre 2024. Il forum riunisce esperti del settore, imprenditori, investitori e leader di pensiero per discutere le ultime intuizioni e tendenze dell'industria medica.
Brad Hauser, CEO di Autonomix, presenterà la tecnologia della piattaforma di rilevamento nervoso minimamente invasivo, ablazione e verifica dell'azienda. Questa tecnologia innovativa utilizza un antenna a matrice di microchip basata su catetere che può rilevare e differenziare i segnali neurali con una sensibilità fino a 3.000 volte superiore rispetto alle tecnologie attuali. La piattaforma include anche una tecnologia di ablazione a radiofrequenza (RF) proprietaria per il trattamento mirato dei nervi, offrendo un approccio guidato dalla precisione per affrontare varie condizioni, dalla gestione del dolore cronico all'ipertensione e alla cardiologia.
Autonomix Medical, Inc. (NASDAQ: AMIX), una empresa centrada en el avance de tratamientos precisos dirigidos a nervios, ha sido seleccionada para una presentación destacada en el 2024 Octane Medical Innovation Forum que se llevará a cabo en Irvine, California, el 8 y 9 de octubre de 2024. El foro reúne a expertos de la industria, emprendedores, inversionistas y líderes de pensamiento para discutir las últimas perspectivas y tendencias en la industria médica.
Brad Hauser, CEO de Autonomix, presentará sobre la tecnología de plataforma de detección nerviosa mínimamente invasiva, ablación y verificación de la empresa. Esta tecnología de primera clase utiliza un antena de matriz de microchip basada en catéter que puede detectar y diferenciar señales neuronales con una sensibilidad hasta 3,000 veces mayor que las tecnologías actuales. La plataforma también incluye tecnología de ablación de radiofrecuencia (RF) patentada para el tratamiento dirigido de los nervios, ofreciendo un enfoque guiado por la precisión para abordar diversas condiciones, desde manejo del dolor crónico hasta hipertensión y cardiología.
Autonomix Medical, Inc. (NASDAQ: AMIX)는 정밀 신경 타겟 치료의 발전에 중점을 둔 회사로, 2024년 10월 8-9일 캘리포니아 어바인에서 개최되는 2024 Octane Medical Innovation Forum에서 특별 포커스 발표를 위해 선정되었습니다. 이 포럼은 산업 전문가, 기업가, 투자자 및 사상 리더들을 모아 의료 산업의 최신 통찰과 트렌드를 논의합니다.
Autonomix의 CEO인 브래드 하우저는 회사의 최소 침습적인 신경 감지, 제거 및 검증 플랫폼 기술에 대해 발표할 것입니다. 이 최초의 기술은 카테터 기반의 마이크로칩 감지 배열 안테나를 사용하여 신경 신호를 현재 기술보다 최대 3,000배 더 높은 민감도로 감지하고 구별할 수 있습니다. 이 플랫폼은 또한 표적 신경 치료를 위한 독점적인 고주파(RF) 제거 기술을 포함하여 만성 통증 관리부터 고혈압 및 심장병에 이르기까지 다양한 상태를 해결하는 정밀 유도 접근 방식을 제공합니다.
Autonomix Medical, Inc. (NASDAQ: AMIX), une entreprise axée sur l'avancement des traitements précis ciblant les nerfs, a été séléctionnée pour une présentation en podium remarquée lors du 2024 Octane Medical Innovation Forum à Irvine, Californie, les 8 et 9 octobre 2024. Le forum rassemble des experts de l'industrie, des entrepreneurs, des investisseurs et des leaders d'opinion pour discuter des dernières perspectives et tendances dans l'industrie médicale.
Brad Hauser, PDG d'Autonomix, présentera la technologie de plateforme de détection nerveuse, d'ablation et de vérification minimement invasive de l'entreprise. Cette technologie, pionnière dans son domaine, utilise une antenne à matrice de microchip à base de cathéter capable de détecter et de différencier les signaux neuronaux avec une sensibilité jusqu'à 3 000 fois supérieure à celle des technologies actuelles. La plateforme comprend également une technologie d'ablation à radiofréquence (RF) propriétaire pour le traitement ciblé des nerfs, offrant une approche guidée par précision pour traiter diverses conditions allant de la gestion de la douleur chronique à l'hypertension et à la cardiologie.
Autonomix Medical, Inc. (NASDAQ: AMIX), ein Unternehmen, das sich auf die Weiterentwicklung von präzisen nervenfokussierten Behandlungen konzentriert, wurde für eine herausragende Podiumspräsentation beim 2024 Octane Medical Innovation Forum in Irvine, Kalifornien, am 8. und 9. Oktober 2024 ausgewählt. Das Forum bringt Branchenexperten, Unternehmer, Investoren und Vordenker zusammen, um die neuesten Erkenntnisse und Trends der Medizinbranche zu diskutieren.
Brad Hauser, CEO von Autonomix, wird über die minimalinvasive Nervenführungs-, Abtragungs- und Verifikationstechnologie des Unternehmens präsentieren. Diese erstklassige Technologie nutzt eine katheterbasierte Mikrosensorantenne, die neuronale Signale mit bis zu 3.000-mal höherer Empfindlichkeit als aktuelle Technologien erkennen und unterscheiden kann. Die Plattform umfasst auch proprietäre Hochfrequenz-(HF)-Abtragungstechnologie für gezielte Nervenbehandlungen, die einen präzisionsgesteuerten Ansatz zur Behandlung verschiedener Erkrankungen von chronischem Schmerzmanagement bis hin zu Hypertonie und Kardiologie bietet.
- None.
- None.
THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it has been selected for a featured podium presentation at the 2024 Octane Medical Innovation Forum taking place on October 8-9, 2024 in Irvine, California.
The Octane Medical Innovation Forum brings together industry experts, entrepreneurs, investors and thought leaders for two days of learning, networking and innovation on the latest insights and trends in the medical industry. For more information, visit the event website here.
As part of the podium presentation, Brad Hauser, Chief Executive Officer of Autonomix, will discuss the latest developments in Autonomix’s minimally invasive nerve-sensing, ablation and verification platform technology that has the potential to address a number of disease categories from chronic pain management to hypertension and cardiology.
The Company’s first-in-class technology platform utilizes a catheter-based microchip sensing array antenna that has the ability to detect and differentiate neural signals with up to 3,000 times greater sensitivity than currently available technologies. Once target nerves are identified, Autonomix uses its proprietary radio frequency (RF) ablation technology to kill targeted nerves, enabling a precision guided sense, treat and verify approach to addressing a number of disease categories from chronic pain management to hypertension and cardiology. Current approaches, primarily relying on opioids or invasive ethanol injections, can provide only limited relief and may lead to risky side effects. For more information about the Company’s technology, please visit autonomix.com.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class technology platform includes a catheter-based microchip sensing array that has the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
autonomix@jtcir.com
FAQ
What event is Autonomix Medical (AMIX) presenting at in October 2024?
What is unique about Autonomix Medical's (AMIX) nerve-sensing technology?
What medical conditions can Autonomix Medical's (AMIX) technology potentially address?
How does Autonomix Medical (AMIX) treat targeted nerves?
